As medications like Ozempic transform the health of millions of Americans, some families are discovering a surprising side ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

British consumers and businesses are cautioned against buying sweets from US brand Hershey as they are "unsafe to eat," ...

Bisexual, gay and lesbian medical students are more likely to leave school before graduation, a new study says. These ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

McDonald’s shares have now been cut by analysts three times in as many trading days, with the latest “buy-to-sell” slap from ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite their effectiveness, they ...